Two more generic liraglutide 3 mg products enter US market, FDA listings show
Additional suppliers of generic liraglutide 3 mg could affect price and availability, but the FDA listings contain no pricing, coverage or supply details.
Two more generic versions of liraglutide 3 mg, the daily GLP-1 injection sold for weight management as Saxenda, have reached the US market, ending the stretch in which Teva Pharmaceuticals was the only company selling a generic copy [1].
The FDA's National Drug Code directory lists a Cipla USA liraglutide product under ANDA217234 with a first marketing date of Feb. 25, 2026 [1]. A listing from Orbicular carries a first marketing date of Feb. 26, 2026 [1]. Both are liraglutide 3 mg products, the same active ingredient and 6 mg/mL strength used in Saxenda [1].
Teva's generic liraglutide, approved under ANDA214568, was first marketed Aug. 28, 2025, and its directory entry carries a marketing end date of Sept. 30, 2027 [1]. Teva's product is listed in cartons of five pens, the same count as Saxenda; the Cipla and Orbicular entries are weight-management liraglutide products as well [1].
Biocon Pharma Inc. is listed next, with a first marketing date of March 27, 2026 [1]. The directory does not explain the timing of the four launches or why the additional products did not appear sooner [1].
Not every liraglutide entry in the directory is a finished prescription product. The same query returns 62 results, including bulk ingredient listings from Novo Nordisk, Polypeptide Laboratories and Biocon Limited, plus repackaged brand-name Victoza and Saxenda from a distributor [1]. The directory also does not label which brand product each generic replaces. Victoza and Saxenda both contain liraglutide at 6 mg/mL, though they are approved under different applications and are labeled for different uses [1].
Prices, wholesale costs, insurance coverage and how widely the new generics are stocked at pharmacies do not appear in the listings and have not been disclosed [1]. The FDA cautions that data in this directory is unvalidated and should not be used to make medical care decisions [1].
Why it matters for patients
Liraglutide is a GLP-1 receptor agonist [1]. It is a different molecule from semaglutide, the ingredient in Ozempic, Wegovy and Rybelsus, and from tirzepatide, the ingredient in Mounjaro and Zepbound. A prescription written for one of those drugs does not carry over to liraglutide, or the reverse.
Liraglutide is also a once-daily injection, while semaglutide and tirzepatide products for weight management are injected weekly.
More companies making the same molecule can put downward pressure on prices and reduce the odds of a single supplier running short. That is a general pattern in generic drug markets; the FDA listings contain no price or supply figures, so what the added competition does to the cost of a liraglutide prescription has not been reported.
Patients filling a liraglutide prescription may see a different manufacturer's name on the carton or pen than they saw previously, and pharmacies may substitute among approved generic versions depending on what they have in stock. State rules govern when a pharmacy may switch a prescription from a brand product to a generic without asking the prescriber, and those rules vary by state.
What happens next
Biocon Pharma's liraglutide is listed with a first marketing date of March 27, 2026 [1]. Teva's entry shows a marketing end date of Sept. 30, 2027, which the directory does not explain [1].
Whether additional generic liraglutide products are approved or launched, and how list prices and insurance coverage for the generic versions compare with brand Saxenda, has not been disclosed [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.